Registry update — unassessed
Phase II Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer's Disease
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 1, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The clinical efficacy of senolytics for cognitive outcomes—this was a Phase II feasibility study, not a pivotal trial powered for efficacy. The generalizability to broader populations with Alzheimer's disease or cognitive decline, as the study enrolled only tau PET-positive individuals with specific disease stages. Whether senolytic effects on cellular aging markers translate to clinical benefit in neurodegenerative disease.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- —
- Effect size
- —
- Significance
- Not reported
- Journal
- Washington University School of Medicine
- Published
- Apr 1, 2026
Sources
Primary source
- Washington University School of Medicine ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Phase II Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer's Disease
The objective of the study is to determine the safety, feasibility, and efficacy of senolytics in older adults with amnestic mild cognitive impairment (MCI) or early-stage AD (Clinical Dementia Rating (CDR)=0.5 or 1) who are tau PET positive
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.